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Background: Migraine with aura is a complex neurological disorder modeled in animals by cortical spreading
depression. It is less usual to find complete animal models for the disease so any opportunity to test a human
effect back at the bench is welcome.
Findings: We report the case of a 24 year old woman who developed new onset episodic migraine with visual
aura shortly after treatment initiation with the If ion channel blocker ivabradine for frequency control in
hypertrophic cardiomyopathy. We studied whether ivabradine could alter cortical spreading depression in a suitable
animal model. Sixteen rats received either ivabradine or saline, and the number of depolarization shifts and blood
flow changes induced by cortical spreading depression were measured in both groups. No significant differences
between the ivabradine and saline group were detected.
Conclusions: Ivabradine is an interesting substance since it is known to produce migraine-like phosphenes
frequently and the patient we report developed de novo migraine with aura. However, we were unable to
demonstrate that the drug influences the susceptibility of the brain to cortical spreading depression with acute
administration. The combined data show the relationship of migraine aura to cortical spreading depression may
have some nuances yet to be identified.
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Background
Migraine is a disorder of the brain [1] with recurrent at-
tacks of head pain, photophobia, phonophobia and nau-
sea [2]. About 20-30% of migraineurs also have episodes
with aura, typically preceding the head pain and lasting
between five and sixty minutes [2]. The most frequent
aura symptom is visual disturbance with negative
(scotomas) or positive (flickering lights) visual phenomena
[3]. Somatosensory, motor or aphasic symptoms are also
possible during migraine aura, but less common. The
visual changes often propagate throughout the visual field
at a speed that has been proposed to reflect cortical spread-
ing depression, a process transiently compromising cortical
function [4].
Animal models of migraine are available, but they usu-
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in any medium, provided the original work is pand additional models are hence useful. We report on
the case of a patient with new onset migraine with aura
after treatment initiation with the novel ion channel
blocker ivabradine, and explore the effect of this drug on
the laboratory model of cortical spreading depression.
Case report
The patient, a 24-year-old Caucasian woman, gave a his-
tory of migraine with aura attacks starting about three
years prior to review. There was a clear correlation of
the onset of migraine with aura with treatment initiation
with the If ion channel blocker ivabradine. Before treat-
ment initiation, she had infrequent and low-intensity
headaches without typical migrainous features, and with-
out migraine aura, starting in puberty. With ivabradine
treatment, she suffered from migraine always with aura
at a frequency between once every three months and
several times a week. She rated the headache intensity of
these attacks as seven to ten out of ten on a verbal rating
scale. The pulsating and stabbing pain was usually uni-
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episodes she had nausea, photophobia, phonophobia and
osmophobia, and no cranial autonomic symptoms. The
headache worsened with physical activity. She typically
felt very tired during the pain. Migraine triggers included
alcohol and potentially high altitude.
All migraine attacks were preceded by visual aura last-
ing between 10 and 30 minutes. She then saw flickering
jagged lines, typically in her left visual hemi-field. These
jagged lines developed into growing scotomas during the
evolution of the aura. She never experienced somato-
sensory, motor or aphasic aura. In addition to the clas-
sical aura, the patient also developed phosphenes every
night during dim light conditions.
The family history was positive for occasional head-
aches in her father and infrequent headaches in her
mother. Her brother had headaches when drinking alco-
hol. No clear-cut migrainous features were stated in the
family and nobody in the family had aura.
The patient had a history of severe familial hypertrophic
obstructive cardiomyopathy (HOCM) and suffered several
syncopes and episodes with difficult to control tachycar-
dia. She underwent prophylactic implantation of an auto-
matic implantable cardioverter-defibrillator (AICD) in
2004. The heart condition was well-controlled in terms of
frequency control only after ivabradine 5 mg twice daily
was added to the preexisting therapy with propranolol
40 mg once a day and verapamil 80 mg twice daily.
We discussed the likely migraine with aura-triggering
effect of ivabradine with her cardiologist. However, stop-
ping ivabradine was not an option since it was control-
ling a potentially fatal heart problem.
The patient had previously also been diagnosed with
somnambulism. The patient had a history of infrequent
motion sickness and “seeing stars” when standing up.
The neurological exam and a CT scan of the head with
contrast including CT venography were unremarkable in
the patient. An MRI of the brain could not be performed
because of the AICD device.
Material and methods of the laboratory experiments
Surgical preparation and experimental design
All experiments were conducted under license of the
University of California, San Francisco Institutional Ani-
mal Care and Use Committee and conforming to the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
Male Sprague–Dawley rats (300-380 g) were anesthe-
tized with 60 mg kg–1 sodium pentobarbital intraperitone-
ally (i.p.). The femoral vein and artery were cannulated for
fluid administration and monitoring of blood pressure, re-
spectively (CT-1000+ ALM 932, CWE Inc., Ardmore, PA,
USA). The rats were maintained anesthetized with a
25–35 mg kg–1 h–1 infusion of propofol. The trachealairways were cannulated and ventilated with oxygen
enriched air, 2–3 ml, 80–100 strokes min-1 (Small rodent
ventilator––Model 683, Harvard Instruments, Kent, UK).
End Tidal CO2 was monitored (Capstar––100, CWE Inc.,
Ardmore, PA, USA) and kept between 3.5 and 4.5%. A
thermostatically controlled homeothermic blanket system
was used to keep the body temperature in physiological
range. The blood pressure, end tidal CO2, and tempe-
rature were electronically displayed. The head of the animal
was fixed in a stereotaxic frame. The withdrawal reflex after
paw pinch and testing of the corneal reflexes were recorded
allowing monitoring of the depth of anesthesia. A midline
cutaneous incision was made. A 2 mm craniotomy was
performed at the parietal bone (7 mm posterior and 1 mm
lateral to bregma) using a saline-cooled dental drill. The
dura mater was opened to expose the cortical surface. CSD
was induced by cortical application of a KCl pellet (3 mg)
on the pia mater.
The rats were separated into two groups. Ivabradine
(2 mg/kg, n = 8) was given intravenously (i.v.) after the first
peak of depolarization shift (DC shift) and cerebral blood
flow (CBF) changes induced by CSD. In the control group,
rats were injected with saline (0.9%, n = 8) intravenously.
DC shift and CBF monitoring
Cortical activity was monitored via another craniotomy
done 1 mm anterior and 1 mm lateral to the bregma. A
glass microelectrode was filled with NaCl 4 M and then
an Ag/AgCl wire was inserted perpendicular to the cor-
tex to a depth of 800–1000 μm from cortical surface
using a micromanipulator. Another Ag/AgCl electrode
was fixed to the nose, which was used as a reference.
After the microelectrode was inserted, the fiber optic
needle probe of laser Doppler flow meter (Wavelength
780 nm) (VMS-LDF2, Moor Instruments, UK) was
placed adjacent to the microelectrode. The tip of the
probe was kept at a distance of 1 mm above the cortical
surface. All tracings were displayed and saved on a per-
sonal computer using an online data analysis system
(Spike5, CED UK). The number of peaks of CSD-evoked
DC shifts and CBF in the first hour was counted.
Data analysis
All data are presented as mean ± standard error. Statis-
tical analysis was carried out using SPSS (19.0, IL, USA).
The DC shift and CBF were analyzed for possible statis-
tical significance between the ivabradine and control
groups using Student’s t-test. A value of P < 0.05 was
considered statistically significant.
Results of laboratory experiments
End-tidal CO2 was 4.64 ± 0.11% (n = 8, mean ± SD) and
4.61 ± 0.14% (n = 8) in the control and ivabradine
groups, respectively.
Figure 1 The effect of ivabradine (2 mg/kg, i.v.) on the number
of peak hyperemias in cortical blood flow and the number of
depolarization shifts induced by cortical spreading depression.
No significant effects are seen in either measurement.
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Topical application of KCl to the cortex triggered a
series of DC shifts and cortical hyperemias characteristic
of CSD. The number of CSDs was 9 ± 2, and 9 ± 1 in
control and ivabradine treated groups, respectively.
There was no significant difference between the
ivabradine treated group compared with the control
group in terms of CSDs (t14 = 0.0001, P = 1.000, Table 1).
In addition, the amplitude and duration of individual
DC shifts was measured. The amplitude of DC shifts
was 19.7 ± 3.2 and 21.4 ± 3.8 mV and the duration was
46.8 ± 12.6 and 45.0 ± 15.0 seconds in control and
ivabradine treated groups, respectively. The difference
was not statistically significant for the amplitude (t14 =
1.413, P = 0.180) and the duration (t14 = 0.313, P = 0.755;
Table 1).
The number of peak hyperemic events was similar:
11 ± 1, and 10 ± 1 peaks in the first hour in the control
and ivabradine treated groups, respectively (t14 = 1.024,
P = 0.323; Table 1). The percent change from baseline of
peak hyperemia was 198 ± 43 and 216 ± 40 (t14 = 1.168,
P = 0.262; Table 1) and the duration of peak hyperemias
was 101.4 ± 47.4 and 117.0 ± 29.4 seconds (t14 = 0.895,
P = 0.395; Table 1) in the control and ivabradine treated
groups, respectively. There was no significant difference
between the ivabradine treated group compared with the
control group (Figure 1).
Effect of ivabradine on cardiovascular response
Ivabradine given intravenously at a dose of 2 mg kg-1
significantly decreased the heart rate with a maximum
effect of 13% at 60 minutes after application (F2.2,0 =
15.008, P = 0.001; Figure 1). The independent t-test
showed significant results from 20 minutes (t7 = 3.297,
P = 0.013) to 60 minutes (t7 = 4.637, P = 0.002) after in-
jection, when compared with baseline. Ivabradine did
not elicit any significant blood pressure changes (F2.13 =
3.010, P = 0.088), nor did the control saline administra-
tion (F2.16 = 1.849, P = 0.188).Table 1 The effect of ivabradine 2 mg/kg i.v. on the
depolarization shifts and cerebral blood flow induced by
cortical spreading depression (3 mg solid KCl)
Control Ivabradine P-value
(n = 8) (n = 8)
Depolarization shift
- Number of peaks in first hour 9 ± 2 9 ± 1 1.000
- Amplitude (mV) 19.7 ± 3.2 21.4 ± 3.8 0.180
- Duration (s) 46.8 ± 12.6 45.0 ± 15.0 0.755
Cerebral blood flow
- Number of peaks in first hour 11 ± 1 10 ± 1 0.323
- Amplitude (%change from baseline) 198 ± 43 216 ± 40 0.262
- Duration (s) 101.4 ± 47.4 117.0 ± 29.4 0.395Discussion
We report the case of a patient with new onset migraine
with typical visual aura after treatment initiation with
ivabradine. Ivabradine is a novel If ion channel blocker in
sinoatrial node cells and blocker of Ih channels in the ret-
ina and brain. It is indicated for patients with chronic
stable angina pectoris due to coronary heart disease, when
patients have contraindications for beta-blockers or com-
bination therapy with a beta-blocker is necessary. In our
patient, ivabradine was used for frequency control in se-
vere HOCM. There was a clear time-locked relationship
between ivabradine treatment start and onset of migraine
with aura as well as onset of nightly phosphenes.
A relation between ivabradine and migraine with aura
has to our knowledge not been described in the literature,
although headache seems to be common (see Ivabradine
prescribing information), as with many other drugs. Phos-
phenes are a well-known side effect of ivabradine occur-
ring in about 15% of patients in the clinical development
program [5]. This is thought to be related to its action at
the retinal Ih channels leading to an inhibition of
hyperpolarization-activated current. However, a cortical
mechanism is possible as the same channels are also abun-
dant in the cortex and thalamus [6,7]. Phosphenes are
common, although there is only a low passage of
ivabradine across the blood retinal and minimal blood
brain barrier passage [8], so a small amount of the drug
seems to suffice.
Ih channels are thought to have a role in modulating
neuronal excitability and in light of the clinical observa-
tion of new onset migraine with ivabradine, we hypothe-
sized that ivabradine may have an effect on the cortical
susceptibility to cortical spreading depression (CSD). As
the aura symptoms were lateralized to the left visual
hemifield and were quite typical for migraine aura, we
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cortical instead of retinal, where one would rather ex-
pect monocular visual symptoms or visual symptoms
throughout the entire visual field. Interestingly, the ani-
mal experiments were unable to demonstrate any effect
of ivabridine on CSD. There are several possible expla-
nations for the absence of an effect: 1. the ivabradine ef-
fect could be via a different - non-CSD mediated
mechanism; 2. the clinical observation could have hap-
pened by chance although this seems unlikely given the
strong temporal relationship and the known mechanism
of action of the drug, as well as the frequent phosphenes
in the patient; 3. the intravenous drug dose used in the
animal experiment may have been too low to produce a
measurable effect as only a small proportion of the drug
is crossing the blood–brain barrier [5]. We applied a
dose of 2 mg/kg, whereas a typical dose used in clinical
practice is 5 mg bid via an oral route. Hence, with an
oral bioavailability of about 40% [9], the weight-adjusted
dose used in the animal experiment was many times
higher than the human dose, making it unlikely that a
dosing problem was the reason for the negative results.
The dose did alter heart rate by 13%, which suggests it
was biologically active. Lastly, it may be that prolonged
dosing is required for an effect [10]. This is not the case
for topiramate when used at a clinical dose [11] nor with
recently identified effects on ASIC channels [12]. This
may highlight the extent of what we are yet to learn
about CSD. Certainly the ability to use acute administra-
tion to screen treatments would be a great advantage.
In conclusion, the clinical case suggests that ivabradine
may have facilitatory effects on the development of mi-
graine aura. Such effects may not be directly related to
CSD, or may require time to develop. Further knowledge
about the exact biological and clinical properties of
ivabradine with its more widespread use may help to
understand better the frequency of effects on migraine
and aura as well as the potential mechanisms. The case
serves to remind us that the translation from bench to
bedside and back has much to offer and continues to
challenge our understanding of migraine mechanisms.
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